AIs	Aromatase Inhibitors
BC	Breast Cancer
CDK 4/6	Cyclin Dependent Kinase 4/6
CIs	Confidence Intervals
EMA	European Medicine Agency
ET	Endocrine Therapy
FDA	Food and Drug Administration
HR+	Hormone Receptor Positive
IPD	Individual Patient data
MBC	Metastatic Breast Cancer
NSAI	Non Steroidal Aromatase Inhibitors
ORR	Objective Response Rate
OS	Overall Survival
PFS	Progression-Free Survival
SOC	Standard Of Care
TFI	Treatment-Free Interval
TTP	Time To Progression